Chinese authorities have approved conducting COVID-19 clinical trials in humans, the Institute of Microbiology at the Chinese Academy of Sciences which is developing the vaccine noted.
According to Xinhua, the recombinant protein vaccine will be tested in Chongqing and Beijing hospitals. The purpose of the first stage of the study is to determine whether it is safe for people.
This is the third type of COVID-19 vaccine, created by Chinese scientists and switched to clinical trials.
Clinical trials of vaccines are usually divided into 3 stages. The first stage of clinical trials mainly assesses safety, and the second stage - safety and immunogenicity of the vaccine, as well as the immunization procedure itself. The third stage of clinical trials assesses the safety and effectiveness of the vaccine in a larger population.